Manufacturer of Controlled Substances; Notice of Application, 9593 [E8-3177]

Download as PDF Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administrator, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 21, 2008. Dated: February 13, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–3175 Filed 2–20–08; 8:45 am] Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 10, 2008, Roche Diagnostics Operations, Inc., Attn: Regulatory Compliance, 9115 Hague Road, Indianapolis, Indiana 46250, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Schedule pwalker on PROD1PC71 with NOTICES I I I II II II II The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement 16:34 Feb 20, 2008 Jkt 214001 BILLING CODE 4410–09–P DEPARTMENT OF LABOR Employment and Training Administration BILLING CODE 4410–09–P [TA–W–62,422] Curtain & Drapery Fashions Including On-Site Leased Workers From Paychex Business Solutions, Lowell, NC; Amended Certification Regarding Eligibility To Apply for Worker Adjustment Assistance and Alternative Trade Adjustment Assistance Manufacturer of Controlled Substances; Notice of Registration Drug Enforcement Administration VerDate Aug<31>2005 Dated: February 12, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–3179 Filed 2–20–08; 8:45 am] Drug Enforcement Administration DEPARTMENT OF JUSTICE Lysergic acid diethylamide (7315) Tetrahydrocannabinols (THC) (7370). Alphamethadol (9605) .................. Hydromorphone (9150) ................ Benzoylecgonine (9180) ............... Methadone (9250) ........................ Morphine (9300) ........................... Dated: February 12, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–3177 Filed 2–20–08; 8:45 am] and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. DEPARTMENT OF JUSTICE BILLING CODE 4410–09–P Drug Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 21, 2008. 9593 By Notice dated September 21, 2007, and published in the Federal Register on September 27, 2007, (72 FR 54930), ISP Freetown Fine Chemicals, 238 South Main Street, Assonet, Massachusetts 02702, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule 2,5–Dimethoxyamphetamine (7396). Amphetamine (1100) .................... Phenylacetone (8501) .................. I II II The company plans to manufacture Phenylacetone to be used in the manufacture of Amphetamine for distribution to its customers. The bulk 2,5–Dimethoxyamphetamine will be used for conversion into non-controlled substances. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of ISP Freetown Fine Chemicals to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated ISP Freetown Fine Chemicals to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 In accordance with section 223 of the Trade Act of 1974 (19 U.S.C. 2273), and section 246 of the Trade Act of 1974 (26 U.S.C. 2813), as amended, the Department of Labor issued a Certification of Eligibility to Apply for Worker Adjustment Assistance and Alternative Trade Adjustment Assistance on December 19, 2007, applicable to workers of Curtain & Drapery Fashions, Lowell, North Carolina. The notice was published in the Federal Register on January 16, 2008 (72 FR 2943). At the request of the State agency, the Department reviewed the certification for workers of the subject firm. The workers were engaged in the production of curtains, bedspreads and comforters. New information shows that leased workers of Paychex Business Solutions were employed on-site at the Lowell, North Carolina location of Curtain & Drapery Fashions. The Department has determined that these workers were sufficiently under the control of Curtain & Drapery Fashions to be considered leased workers. Based on these findings, the Department is amending this certification to include leased workers of Paychex Business Solutions working on-site at the Lowell, North Carolina location of the subject firm. The intent of the Department’s certification is to include all workers employed at Curtain & Drapery Fashions, Lowell, North Carolina who were adversely impacted by increased customer imports of curtains, bedspreads and comforters. E:\FR\FM\21FEN1.SGM 21FEN1

Agencies

[Federal Register Volume 73, Number 35 (Thursday, February 21, 2008)]
[Notices]
[Page 9593]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-3177]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on January 10, 2008, Roche 
Diagnostics Operations, Inc., Attn: Regulatory Compliance, 9115 Hague 
Road, Indianapolis, Indiana 46250, made application by renewal to the 
Drug Enforcement Administration (DEA) as a bulk manufacturer of the 
basic classes of controlled substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide (7315)..........  I
Tetrahydrocannabinols (THC) (7370).........  I
Alphamethadol (9605).......................  I
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Methadone (9250)...........................  II
Morphine (9300)............................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances for use in diagnostic products.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administration, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537, or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than April 21, 2008.

    Dated: February 12, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E8-3177 Filed 2-20-08; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.